Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Momenta Pharmaceuticals Fell for a Second Straight Day

By Brian Orelli, PhD - Dec 11, 2018 at 5:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Volatility strikes the biotech.

What happened

After jumping 18% on Friday following its successful raise of $200 million, Momenta Pharmaceuticals (MNTA) proceeded to fall 9.5% yesterday and 10.4% today, giving up all of its gains and then some.

Welcome to volatile biotech investing in a company with clinical data that's largely years away.

So what

Momenta's lead novel asset, M281, isn't scheduled to read out phase 2 data until 2020 and 2021 for the two immunological diseases that Momenta is targeting. A proof-of-concept study for an autoimmune disease drug, M254, is scheduled to start later this year or early in 2019, putting a readout in 2020.

Investors might get to see clinical data in 2019 from a phase 1 study for M230, which is partnered with CSL, but that's very early-stage.

Since biotech valuation can often be more art than science, a dearth of valuation-changing data can result in substantial volatility as investor sentiment changes.

Man in front of monitors displaying stock charts, clenching fists to his head

Image source: Getty Images.

Now what

In addition to its novel pipeline, Momenta also has a couple of biosimilar drugs: M923, a biosimilar to Humira that's wholly owned, and M710, a biosimilar to Eylea that's in phase 3 development being run by partner Mylan.

M923 is ready to be submitted to regulators, and Momenta has signaled that it would like to find a partner to take over the commercialization, so that news could drop at any point.

Until then, long-term investors can just ignore the double-digit stock price changes on no news, and wait for clinical trial data that will change the biotech's valuation fundamentally.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.